Morphine, oxycodone, methadone and its enantiomers in different models of nociception in the rat

Anesthesia and Analgesia

Volumn 102, Issue 6, 2006, Pages 1768-1774

  Lemberg, Kim ^b   Kontinen, Vesa K ^b   Viljakka, Kaarin ^b   Kylänlahti, Irene ^b   Yli Kauhaluoma, Jari ^b   Kalso, Eija ^a  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

METHADONE; MORPHINE; MU OPIATE RECEPTOR AGONIST; OXYCODONE; SODIUM CHLORIDE;

ALLODYNIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINOCICEPTION; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG POTENCY; ENANTIOMER; HOT PLATE TEST; LOCOMOTION; MALE; NERVE INJURY; NERVE LIGATION; NEUROPATHIC PAIN; NOCICEPTION; NONHUMAN; PRIORITY JOURNAL; RAT; SPINAL NERVE; TAIL FLICK TEST;

EID: 33744494539     PISSN: 00032999     EISSN: None     Source Type: Journal    
DOI: 10.1213/01.ane.0000205751.88422.41     Document Type: Article

References (37)

1. Kristensen K, Christensen CB, Christrup LL. The mu1, mu2, delta, kappa opioid receptor binding profiles of methadone stereoisomers and morphine. Life Sci 1995;56:PL45-50.
2. Monory K, Greiner E, Sartania N, et al. Opioid binding profiles of new hydrazone, oxime, carbazone and semicarbazone derivatives of 14-alkoxymorphinans. Life Sci 1999;64:2011-20.
3. Kalso E, Vainio A. Morphine and oxycodone hydrochloride in the management of cancer pain. Clin Pharmacol Ther 1990;47: 639-46.
4. Kaiko RF, Benziger DP, Fitzmartin RD, et al. Pharmacokinetic- pharmacodynamic relationships of controlled-release oxycodone. Clin Pharmacol Ther 1996;59:52-61.
5. Heiskanen T, Olkkola KT, Kalso E. Effects of blocking CYP2D6 on the pharmacokinetics and pharmacodynamics of oxycodone. Clin Pharmacol Ther 1998;64:603-11.
6. Bruera E, Pereira J, Watanabe S, et al. Opioid rotation in patients with cancer pain. A retrospective comparison of dose ratios between methadone, hydromorphone, and morphine. Cancer 1996;78:852-7.
7. Crews JC, Sweeney NJ, Denson DD. Clinical efficacy of methadone in patients refractory to other mu-opioid receptor agonist analgesics for management of terminal cancer pain: case presentations and discussion of incomplete cross-tolerance among opioid agonist analgesics. Cancer 1993;72:2266-72.
8. Leng G, Finnegan MJ. Successful use of methadone in nociceptive cancer pain unresponsive to morphine. Palliat Med 1994;8: 153-5.
9. Vigano A, Fan D, Bruera E. Individualized use of methadone and opioid rotation in the comprehensive management of cancer pain associated with poor prognostic indicators. Pain 1996; 67:115-9.
10. Manfredi PL, Borsook D, Chandler SW, Payne R. Intravenous methadone for cancer pain unrelieved by morphine and hydromorphone: clinical observations. Pain 1997;70:99-101.
11. Ebert B, Andersen S, Hjeds H, Dickenson AH. Dextropropoxyphene acts as a noncompetitive N-methyl-D-aspartate antagonist. J Pain Symptom Manage 1998;15:269-74.
12. Andersen S, Dickenson AH, Kohn M, et al. The opioid ketobemidone has a NMDA blocking effect. Pain 1996;67:369-74.
13. Ebert B, Andersen S, Krogsgaard-Larsen P. Ketobemidone, methadone and pethidine are non-competitive N-methyl-D-aspartate (NMDA) antagonists in the rat cortex and spinal cord. Neurosci Lett 1995;187:165-8.
14. Mao J, Price D, Mayer DJ. Mechanisms of hyperalgesia and morphine tolerance: a current view of their possible interactions. Pain 1995;62:259-74.
15. Wiesenfeld-Hallin Z. Combined opioid-NMDA antagonist therapies. What advantages do they offer for the control of pain syndromes? Drugs 1998;55:1-4.
16. Trujillo KA, Akil H. Inhibition of morphine tolerance and dependence by the NMDA receptor antagonist MK-801. Science 1991;251:85-7.
17. Grass S, Hoffmann O, Xu XJ, Wiesenfeld Hallin Z. N-methyl-D-aspartate receptor antagonists potentiate morphine's antinociceptive effect in the rat. Acta Physiol Scand 1996;158:269-73.
18. Kim HS, Jang CG, Park WK, Inhibition by MK-801 of morphine-induced conditioned place preference and postsynaptic dopamine receptor supersensitivity in mice. Pharmacol Biochem Behav 1996;55:11-7.
19. Gorman AL, Elliott KJ, Inturrisi CE. The d- and 1-isomers of methadone bind to the non-competitive site on the N-methyl-D-aspartate (NMDA) receptor in rat forebrain and spinal cord. Neurosci Lett 1997;223:5-8.
20. Horng JS, Smits SE, Wong DT. The binding of the optical isomers of methadone, alpha-methadol, alpha-acetylmethadol and their N-demethylated derivatives to the opiate receptors of rat brain. Res Commun Chem Pathol Pharmacol 1976;14:621-9.
21. Zimmermann M. Ethical guidelines for investigation of experimental pain in conscious animals. Pain 1983;16:109-10.
22. Howe E, Sletzinger M. Resolution of dl-methadone and dl-isomethadone. J Am Chem Soc 1949;71:2935-6.
23. Elks J. Methadone. In: Elks J, ed. Dictionary of drugs. London: Chapman and Hall, 1990:781.
24. Kim SH, Chung JM. An experimental model for peripheral neuropathy produced by segmental spinal nerve ligation in the rat. Pain 1992;50:355-63.
25. Choi Y, Yoon YW, Na HS, et al. Behavioral signs of ongoing pain and cold allodynia in a rat model of neuropathic pain. Pain 1994;59:369-76.
26. Chen ZR, Irvine RJ, Somogyi AA, Bochner F. Mu receptor binding of some commonly used opioids and their metabolites. Life Sci 1991;48:2165-71.
27. Pöyhia R, Kalso EA. Antinociceptive effects and central nervous system depression caused by oxycodone and morphine in rats. Pharmacol Toxicol 1992;70:125-30.
28. Thompson CM, Wojno H, Greiner E, et al. Activation of G-proteins by morphine and codeine congeners: insights to the relevance of O- and N-demethylated metabolites at mu- and delta-opioid receptors. J Pharmacol Exp Ther 2004;308:547-54.
29. McQuay HJ, Sullivan AF, Smallman K, Dickenson AH. Intrathecal opioids, potency and lipophilicity. Pain 1989;36:111-5.
30. Watson CP, Babul N. Efficacy of oxycodone in neuropathic pain: a randomized trial in postherpetic neuralgia. Neurology 1998; 50:1837-41.
31. Gimbel JS, Richards P, Portenoy RK. Controlled-release oxycodone for pain in diabetic neuropathy: a randomized controlled trial. Neurology 2003;60:927-34.
32. Raja SN, Haythornthwaite JA, Pappagallo M, et al. Opioids versus antidepressants in postherpetic neuralgia: a randomized, placebo-controlled trial. Neurology 2002;59:1015-21.
33. Shimoyama N, Shimoyama M, Elliott KJ, Inturrisi CE. d-Methadone is antinociceptive in the rat formalin test. J Pharmacol Exp Ther 1997;283:648-52.
34. Chizh BA, Schlutz H, Scheede M, Englberger W. The N-methyl-D-aspartate antagonistic and opioid components of d-methadone antinociception in the rat spinal cord. Neurosci Lett 2000;296:117-20.
35. Bolan EA, Tallarida RJ, Pasternak GW. Synergy between mu opioid ligands: evidence for functional interactions among mu opioid receptor subtypes. J Pharmacol Exp Ther 2002;303: 557-62.
36. Davis AM, Inturrisi CE. d-Methadone blocks morphine tolerance and N-methyl-D-aspartate-induced hyperalgesia. J Pharmacol Exp Ther 1999;289:1048-53.
37. Carpenter KJ, Chapman V, Dickenson AH. Neuronal inhibitory effects of methadone are predominantly opioid receptor mediated in the rat spinal cord in vivo. Eur J Pain 2000;4:19-26.